Faricimab, sold under the brand name Vabysmo ( ), is a monoclonal antibody used for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Faricimab is the first bispecific monoclonal antibody to target both vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2). By targeting these pathways, faricimab stabilizes blood vessels in the retina. It is given by intravitreal injection (injection into the eye) by an ophthalmologist.
via Wikipedia infobox
Faricimab, sold under the brand name Vabysmo ( ), is a monoclonal antibody used for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Faricimab is the first bispecific monoclonal antibody to target both vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2). By targeting these pathways, faricimab stabilizes blood vessels in the retina. It is given by intravitreal injection (injection into the eye) by an ophthalmologist.
Faricimab was developed by Roche in Penzberg (Roche Innovation Center Munich). Faricimab was approved for medical use in the United States in January 2022, and in the European Union in September 2022.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).